ARS Pharmaceuticals Inc (SPRY)
13.38
-0.17
(-1.25%)
USD |
NASDAQ |
Nov 21, 16:00
13.95
+0.57
(+4.26%)
After-Hours: 05:07
ARS Pharmaceuticals Enterprise Value: 1.096B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 1.096B |
| November 20, 2024 | 1.112B |
| November 19, 2024 | 1.136B |
| November 18, 2024 | 1.135B |
| November 15, 2024 | 1.157B |
| November 14, 2024 | 1.167B |
| November 13, 2024 | 1.164B |
| November 12, 2024 | 1.410B |
| November 11, 2024 | 1.495B |
| November 08, 2024 | 1.451B |
| November 07, 2024 | 1.364B |
| November 06, 2024 | 1.323B |
| November 05, 2024 | 1.284B |
| November 04, 2024 | 1.272B |
| November 01, 2024 | 1.278B |
| October 31, 2024 | 1.225B |
| October 30, 2024 | 1.182B |
| October 29, 2024 | 1.269B |
| October 28, 2024 | 1.252B |
| October 25, 2024 | 1.230B |
| October 24, 2024 | 1.291B |
| October 23, 2024 | 1.355B |
| October 22, 2024 | 1.426B |
| October 21, 2024 | 1.420B |
| October 18, 2024 | 1.349B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.362B |
| October 16, 2024 | 1.400B |
| October 15, 2024 | 1.275B |
| October 14, 2024 | 1.248B |
| October 11, 2024 | 1.206B |
| October 10, 2024 | 1.147B |
| October 09, 2024 | 1.127B |
| October 08, 2024 | 1.144B |
| October 07, 2024 | 1.122B |
| October 04, 2024 | 1.174B |
| October 03, 2024 | 1.155B |
| October 02, 2024 | 1.199B |
| October 01, 2024 | 1.200B |
| September 30, 2024 | 1.204B |
| September 27, 2024 | 1.169B |
| September 26, 2024 | 1.188B |
| September 25, 2024 | 1.143B |
| September 24, 2024 | 1.107B |
| September 23, 2024 | 1.147B |
| September 20, 2024 | 1.213B |
| September 19, 2024 | 1.222B |
| September 18, 2024 | 1.143B |
| September 17, 2024 | 1.046B |
| September 16, 2024 | 1.037B |
| September 13, 2024 | 1.071B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
26.85M
Minimum
Sep 20 2023
1.495B
Maximum
Nov 11 2024
556.16M
Average
497.44M
Median
May 12 2023
Enterprise Value Benchmarks
| Exelixis Inc | 8.758B |
| Assembly Biosciences Inc | -1.389M |
| Protagonist Therapeutics Inc | 2.014B |
| Precision BioSciences Inc | -29.06M |
| Avidity Biosciences Inc | 3.489B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.13M |
| Revenue (Quarterly) | 2.068M |
| Total Expenses (Quarterly) | 23.82M |
| EPS Diluted (Quarterly) | -0.20 |
| Gross Profit Margin (Quarterly) | 94.58% |
| Profit Margin (Quarterly) | -925.0% |
| Earnings Yield | -3.81% |
| Normalized Earnings Yield | -3.812 |